Literature DB >> 26049818

Imaging of the Posttherapeutic Brain.

Bruno A Telles1, Francesco D'Amore, Alexander Lerner, Meng Law, Mark S Shiroishi.   

Abstract

This review covers important topics relating to the imaging evaluation of glioblastoma multiforme after therapy. An overview of the Macdonald and Response Assessment in Neuro-Oncology criteria as well as important questions and limitations regarding their use are provided. Pseudoprogression and pseudoresponse as well as the use of advanced magnetic resonance imaging techniques such as perfusion, diffusion, and spectroscopy in the evaluation of the posttherapeutic brain are also reviewed.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26049818     DOI： 10.1097/RMR.0000000000000051

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN： 0899-3459


  4 in total

1.  Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.

Authors:  Csanad G Varallyay; Eric Nesbit; Andrea Horvath; Peter Varallyay; Rongwei Fu; Seymur Gahramanov; Leslie L Muldoon; Xin Li; William D Rooney; Edward A Neuwelt
Journal:  J Magn Reson Imaging       Date:  2018-01-04       Impact factor: 4.813

2.  Differentiation of residual/recurrent gliomas from postradiation necrosis with arterial spin labeling and diffusion tensor magnetic resonance imaging-derived metrics.

Authors:  Ahmed Abdel Khalek Abdel Razek; Lamiaa El-Serougy; Mohamed Abdelsalam; Gada Gaballa; Mona Talaat
Journal:  Neuroradiology       Date:  2017-12-07       Impact factor: 2.804

Review 3.  High-grade glioma management and response assessment-recent advances and current challenges.

Authors:  M N Khan; A M Sharma; M Pitz; S K Loewen; H Quon; A Poulin; M Essig
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

4.  A Simple Automated Method for Detecting Recurrence in High-Grade Glioma.

Authors:  T K Yanagihara; J Grinband; J Rowley; K A Cauley; A Lee; M Garrett; M Afghan; A Chu; T J C Wang
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-14       Impact factor: 3.825
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.